Literature DB >> 7036482

Alien-driven diversity and alien-selected escape: a rationale for allogeneic cancer immunotherapy.

P M Sondel, J A Hank.   

Abstract

We have presented two theories relating to the function of histocompatibility antigens and their presence as alien antigens on tumor cells. The theory of alien-driven diversity suggests that the ability to effectively recognize pathogens in the form of "altered-self" derives from prior exposure to antigens cross-reactive with "altered-self" during development. Furthermore, these cross-reactive antigens are alloantigens that are expressed on autologous cells during somatic development. These somatically generated alloantigens could be the result of the same genetic alterations that produced the polymorphism of these antigens within the species. Second, the theory of alien-selected escape suggests that a tumorigenic pathogen selects a cell bearing an alien H* antigen so that the alien-infected cell is recognized as self rather than altered-self by the tumor host. We than summarized data from mouse and man consistent with these theories and with the concept that clinically evident tumors have escaped the host's immune system. Finally, we have discussed potential directions for devising immunotherapy with allogeneic cells that might circumvent the apparent unresponsiveness of the patient's immune system to his own tumor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7036482

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  The role of allogeneic cells in the stimulation of cell-mediated cytotoxicity to leukaemia cells. A family study.

Authors:  G M Taylor; B A Bradley
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro.

Authors:  P M Sondel; J A Hank; T Wendel; B Flynn; M J Bozdech
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.